Regentis Biomaterials Receives European Regulatory Approval For New GelrinC Manufacturing Process

Regentis Gets Japan Patent Office Notice of Allowance For Organic Solvent‑Free Protein‑Polymer Conjugate Compositions, Covering GelrinC Manufacturing Process And Ready‑to‑Use Liquid Formulation for Articular Cartilage Repair

Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell

Why Is Regentis Biomaterials Stock Rising On Wednesday?

Regentis Biomaterials Ltd. (RGNT) stock rises after withdrawing its Form F-1 registration statement and accelerating European commercialization for GelrinC.

Regentis Biomaterials Shares Halted On Circuit Breaker To The Upside, Stock now Up 787.33%